Quick Answer
Valion Bio, Inc. reported Stockholders Equity of $16.80 million for fiscal year 2025.
Valion Bio, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $16.80M | +392.0% |
| 2025 | $3.41M | +3.0% |
| 2025 | $3.31M | +30.7% |
| 2024 | $2.54M | -29.2% |
| 2023 | $3.58M | -1.4% |
| 2022 | $3.63M | -72.6% |
| 2021 | $13.27M | +1227.6% |
| 2020 | -$1.18M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.59M | +97.3% | +51.6% |
| June 30, 2025 | $3.69M | -12.0% | +21.4% |
| March 31, 2025 | $3.04M | +41.0% | +19.8% |
| December 31, 2024 | $2.54M | -29.2% | -10.6% |
| September 30, 2024 | $2.83M | -50.8% | -32.4% |
| June 30, 2024 | $4.19M | +32.6% | +94.7% |
| March 31, 2024 | $2.15M | -58.6% | -39.9% |
| December 31, 2023 | $3.58M | -1.4% | -37.9% |
- Valion Bio, Inc. showed an increase of +392.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Valion Bio, Inc.’s stockholders equity has grown by 1527.1% (from -$1.18 million to $16.80 million).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: